{
    "clinical_study": {
        "@rank": "80827", 
        "brief_summary": {
            "textblock": "PRIMARY: To assess the effect of bovine anti-Cryptosporidium immunoglobulin (BACI) on the\n      volume of diarrhea due to Cryptosporidium parvum in AIDS patients who have protracted\n      Cryptosporidium enteritis.\n\n      SECONDARY: To assess changes in stool consistency and frequency, body weight, and safety in\n      this patient population."
        }, 
        "brief_title": "A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients", 
        "condition": [
            "Cryptosporidiosis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Cryptosporidiosis", 
                "Enteritis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Forty patients are randomized to receive either BACI or placebo (bovine colostrum from\n      non-immunized cattle) for 1 week. The double-blind portion of the study will be followed by\n      an open-label phase in which all 40 patients receive BACI for 1 week."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Antidiarrheal compounds (if dose remains stable).\n\n          -  Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), or alternative HIV\n             therapy (provided dose was stable for at least 4 weeks prior to study entry).\n\n        Patients must have:\n\n          -  AIDS.\n\n          -  Cryptosporidium parvum enteritis.\n\n          -  Chronic diarrhea.\n\n          -  Life expectancy of at least 4 weeks.\n\n          -  Ability to tolerate food by mouth.\n\n          -  Ability to take the histamine H2-receptor antagonist famotidine (Pepcid).\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Antidiarrheal compounds (provided dose has remained stable in the 7 days prior to\n             study entry).\n\n          -  Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), or alternative HIV\n             therapy (provided dose has remained stable for at least 4 weeks prior to study\n             entry).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Concurrent unresolved clinical infections with enteric pathogens other than C. parvum\n             (e.g., rotavirus, Salmonella, Shigella, Campylobacter, Giardia, C. difficile toxin,\n             Yersinia, amebiasis, MAI, CMV, Microsporida) as determined by history or routine\n             microbiology screening.\n\n          -  Other acute infections or concurrent immediately life-threatening medical crisis\n             other than cryptosporidiosis.\n\n          -  Grossly bloody diarrhea.\n\n          -  Known allergy to milk or milk products (other than lactose intolerance).\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Other experimental therapy (e.g., macrolide antibiotics, paromomycin) within 30 days\n             prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002248", 
            "org_study_id": "081A", 
            "secondary_id": "UNX-4101"
        }, 
        "intervention": {
            "intervention_name": "Cryptosporidium Immune Whey Protein Concentrate (Bovine)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Antibodies"
            ]
        }, 
        "keyword": [
            "Antidiarrheals", 
            "Cryptosporidiosis", 
            "Diarrhea", 
            "Acquired Immunodeficiency Syndrome", 
            "Cryptosporidium", 
            "Immunization, Passive"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90067"
                    }, 
                    "name": "Gabin Med Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "UCSF - San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "AIDS Research Consortium of Atlanta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02135"
                    }, 
                    "name": "Saint Elizabeth's Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "New England Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Cornell Univ Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Nord J, Ma P, Tacket CO, Dijohn D, Tzipori S, Sahner D, Shieb G. Treatment of AIDS associated cryptosporidiosis with hyperimmune colostrum from cows vaccinated with cryptosporidium. Int Conf AIDS. 1989 Jun 4-9;5:656 (abstract no C586)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002248"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Univax Biologics Inc", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1993"
    }, 
    "geocoordinates": {
        "AIDS Research Consortium of Atlanta": "33.749 -84.388", 
        "Cornell Univ Med Ctr": "40.714 -74.006", 
        "Gabin Med Group": "34.052 -118.244", 
        "New England Med Ctr": "42.358 -71.06", 
        "Saint Elizabeth's Hosp": "42.358 -71.06", 
        "UCSF - San Francisco Gen Hosp": "37.775 -122.419"
    }
}